biote vs Mannatech
BTMD and MTEX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BTMD and MTEX compare
biote is the larger company, worth 3.1 times as much as Mannatech ($38.3M against $12.2M).
Mannatech grew revenue faster over the last twelve months (−6.6% versus −8.6% for biote).
Mannatech keeps more of each dollar of sales as profit, with a net margin of −0.41% compared with −1.1% at biote.
Mannatech scores higher on the StockData Score (9 against 4 for biote), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BTMD | MTEX |
|---|---|---|
| Size and price | ||
| Market cap | $38.3M | $12.2M |
| Share price | $1.06 | $6.30 |
| Change, 1 year | −59.7% | −33.8% |
| Change, 5 years | −89.1% | −83.5% |
| Beta (5Y) | 0.51 | 0.36 |
| Employees | 223 | 387 |
| StockData Score | ||
| Total score | 4 | 9 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 0 |
| Performance score | 2 | 4 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.2× | 0.1× (better) |
| P/B | – | 2.3× |
| EV/EBITDA | 12.2× | 4.8× (better) |
| P/FCF | 5.2× | – |
| FCF yield | 19.4% (better) | −5.3% |
| Fair value | – | $11.41 |
| Margin of safety | – | 44.8% |
| Growth | ||
| Revenue growth (TTM) | −8.6% | −6.6% (better) |
| Revenue growth, 5Y average | – | −6.5% |
| Net income growth (TTM) | −107% | – |
| EPS growth (TTM) | −114% | – |
| Profitability | ||
| Gross margin | 67.5% | 75.7% (better) |
| Operating margin | 5.0% (better) | 0.91% |
| Net margin | −1.1% | −0.41% (better) |
| FCF margin | 4.1% (better) | −0.63% |
| Return on equity | – | −7.0% |
| Return on invested capital | 18.5% (better) | 17.8% |
| Financial health | ||
| Debt / equity | – | 0.53 |
| Net debt / EBITDA | 8.62 (better) | −1.36 |
| Interest coverage | – | 2.0× |
| Current ratio | 1.37 (better) | 1.18 |
| Altman Z-score | 1.65 | 4.10 (better) |
| Piotroski F-score | 6 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | 18.9% | – |
| Shareholder yield | 18.9% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 36.6% | 7.9% |
| Held by insiders | 23.3% | – |
| Insider net buying, 12 months | $202K (better) | $62.2K |
| Short interest, % of float | 3.1% | – |
Go deeper
- BTMD stock overview
- BTMD income statement
- BTMD valuation and score
- MTEX stock overview
- MTEX income statement
- MTEX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.